Bloomberg Law
March 29, 2019, 11:36 AM

AstraZeneca Bets $6.9 Billion in Japan Cancer Therapy Deal (3)

Lisa Du
Lisa Du
Bloomberg News

AstraZeneca Plc forged its biggest deal in more than a decade, agreeing to pay as much as $6.9 billion to buy into a promising Japanese cancer treatment as part of its push to become a global oncology powerhouse.

AstraZeneca will pay the Japanese drugmaker Daiichi Sankyo Co. $1.35 billion upfront to jointly develop and commercialize the cancer therapy trastuzumab deruxtecan, with as much as $5.6 billion in additional payments subject to sales milestones and other contingencies, the companies said late March 28. They will also equally split development and commercialization costs.

The deal fuels a race among big drug companies ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.